晚期结直肠癌中FOLFIRI序贯FOLFOX6或反向序贯的随机GERCOR研究
这项III期随机GERCOR研究比较了晚期结直肠癌中FOLFIRI序贯FOLFOX6(A组)与反向序贯(B组)的疗效。A组109例中位生存21.5个月,B组111例为20.6个月(P=0.99);两组毒性谱不同。结论为两种序贯方案均获得延长生存且疗效相似。
要点
- FOLFIRI序贯FOLFOX6与反向序贯的中位生存分别为21.5个月与20.6个月(P=0.99),疗效相似。
- 一线FOLFIRI的缓解率为56%、中位无进展生存8.5个月;FOLFOX6为54%、8.0个月(P=0.26)。
- 一线FOLFIRI更常见3/4级黏膜炎、恶心呕吐及2级脱发;FOLFOX6更常见3/4级中性粒细胞减少和神经感觉毒性。
核心结论
- 两种序贯方案均获得延长生存且疗效相似,毒性谱不同。
研究设计与样本
- III期随机GERCOR研究,纳入既往未治疗的晚期结直肠癌可评估患者,随机分为A组(FOLFIRI序贯FOLFOX6,109例)与B组(FOLFOX6序贯FOLFIRI,111例)。
- 方案为l-LV 200 mg/m2或dl-LV 400 mg/m2 2小时输注,继以FU 400 mg/m2推注及46小时输注2400至3000 mg/m2,每2周重复;联合伊立替康180 mg/m2或奥沙利铂100 mg/m2(第1天2小时输注)。
- 疾病进展时,A组将伊立替康替换为奥沙利铂,B组将奥沙利铂替换为伊立替康。
主要发现
- A组109例中位生存21.5个月 vs B组111例20.6个月(P=0.99)。
- A组中位第二次无进展生存14.2个月 vs B组10.9个月(P=0.64)。
- 一线FOLFIRI缓解率56%、中位无进展生存8.5个月 vs 一线FOLFOX6缓解率54%、中位无进展生存8.0个月(P=0.26)。
- 二线FOLFIRI缓解率4%、中位无进展生存2.5个月 vs 二线FOLFOX6缓解率15%、中位无进展生存4.2个月。
关键数值与推荐
- 一线FOLFIRI:缓解率56%,中位无进展生存8.5个月;一线FOLFOX6:缓解率54%,中位无进展生存8.0个月(P=0.26)。
- 二线FOLFIRI:缓解率4%,中位无进展生存2.5个月;二线FOLFOX6:缓解率15%,中位无进展生存4.2个月。
- A组中位生存21.5个月 vs B组20.6个月(P=0.99);A组中位第二次无进展生存14.2个月 vs B组10.9个月(P=0.64)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In metastatic colorectal cancer, phase III studies have demonstrated the superiority of fluorouracil (FU) with leucovorin (LV) in combination with irinotecan or oxaliplatin over FU + LV alone. This phase III study investigated two sequences: folinic acid, FU, and irinotecan (FOLFIRI) followed by folinic acid, FU, and oxaliplatin (FOLFOX6; arm A), and FOLFOX6 followed by FOLFIRI (arm B). PATIENTS AND METHODS: Previously untreated patients with assessable disease were randomly assigned to receive a 2-hour infusion of l-LV 200 mg/m2 or dl-LV 400 mg/m2 followed by a FU bolus 400 mg/m2 and 46-hour infusion 2,400 to 3,000 mg/m2 every 46 hours every 2 weeks, either with irinotecan 180 mg/m2 or with oxaliplatin 100 mg/m2 as a 2-hour infusion on day 1. At progression, irinotecan was replaced by oxaliplatin (arm A), or oxaliplatin by irinotecan (arm B). RESULTS: Median survival was 21.5 months in 109 patients allocated to FOLFIRI then FOLFOX6 versus 20.6 months in 111 patients allocated to FOLFOX6 then FOLFIRI (P = .99). Median second progression-free survival (PFS) was 14.2 months in arm A versus 10.9 in arm B (P = .64). In first-line therapy, FOLFIRI achieved 56% response rate (RR) and 8.5 months median PFS, versus FOLFOX6 which achieved 54% RR and 8.0 months median PFS (P = .26). Second-line FOLFIRI achieved 4% RR and 2.5 months median PFS, versus FOLFOX6 which achieved 15% RR and 4.2 months PFS. In first-line therapy, National Cancer Institute Common Toxicity Criteria grade 3/4 mucositis, nausea/vomiting, and grade 2 alopecia were more frequent with FOLFIRI, and grade 3/4 neutropenia and neurosensory toxicity were more frequent with FOLFOX6. CONCLUSION: Both sequences achieved a prolonged survival and similar efficacy. The toxicity profiles were different.
引用
- Tournigand C, André T, Achille E, et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. J Clin Oncol. 2023. PMID: 37379692. doi:10.1200/JCO.22.02774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。